Caffeine increases IOP and OPP in POAG

Article

Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients.

Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients. patients, claims a paper in Eye.

Dr A.Z. Jiwani et al., Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA, conducted a prospective, double-masked, crossover, randomized controlled trial on 106 subjects. Of these participants, 22 had high-tension POAG, 18 had normal tension, 21 POAG suspects and 25 healthy volunteers.

Each subject was given either 237 mL of caffeinated coffee or decaffeinated coffee at the first visit and the alternate beverage on the second visit. The outcome measures included blood pressure (BP) and pascal dynamic contour tonometer measurements of IOP ocular pulse amplitude (OPA) and heart rate. These were all measured before and at 60 and 90 minutes after coffee ingestion.

The results demonstrated no significant difference in baseline IOP, OPP and OPA between caffeinated and decaffeinated drinks. Mean mmHg changes in IOP, OPP and OPA were 0.99, 1.57 and 0.23, at 60 minutes, respectively. The results at 90 minutes for IOP, OPP and OPA were and 1.06, 1.26 and 0.18, respectively.

This suggests that consuming one cup of caffeinated coffee statistically increases but is not likely to clinically impact IOP and OPP in POAG cases.

The abstract can be found here .

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.